Cite
HARVARD Citation
Hochmair, M. et al. (n.d.). Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib. European journal of cancer. pp. S183-S184. [Online].